Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3243-3249

  Botchkina, Galina I ^a   Kim, Roger H ^a   Botchkina, Inna L ^a   Kirshenbaum, Alex ^a   Frischer, Zelik ^a   Adler, Howard L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; TELOMERASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CELL ISOLATION; CELL SEPARATION; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; ENZYME ANALYSIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; INSTRUMENT; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; SENSITIVITY AND SPECIFICITY; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; URINE;

CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPETITIVE SEQUENCES, NUCLEIC ACID; SENSITIVITY AND SPECIFICITY; TELOMERASE; TELOMERE;

EID: 18244400114     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1919     Document Type: Article

References (48)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Kosary CL, Reis LAG, Miller BA, Hankey BF, Narras A, Edwards BK. SEER cancer statistics review, 1973-1992: tables and graphs, National Cancer Institute. NIH Pub. No. 96-2789. Bethesda (MD): National Cancer Institute; 1995.
3. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
4. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages 20-69: an autopsy study of 249 cases. In vivo 1994;8: 439-43.
5. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273: 289-94.
6. Abouelfadel Z, Miller GJ, Glode LM, et al. High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade. Clin Prostate Cancer 2002;1:115-7.
7. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL. BJU Int 2004;93:499-502.
8. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994;151:1571-4.
9. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 2000;164:388-92.
10. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163: 1144-8;1148-9.
11. Wullich B, Rohde V, Oehlenschlager B, et al. Focal intratumoral heterogeneity for telomerase activity in human prostate cancer. J Urol 1999;161: 1997-2001.
12. Garret M, Jassie M. Cytologic examination of post prostatic massage specimens as an aid in diagnosis of carcinoma of the prostate. Acta Cytol 1976;20: 126-31.
13. Bologna M, Vicentini C, Festuccia C, et al. Early diagnosis of prostatic carcinoma based on in vitro culture of viable tumor cells harvested by prostatic massage. Eur Urol 1988;14:474-6.
14. Bologna M, Vicentini C, Corrao G, et al. Early diagnosis of prostatic carcinoma may be achieved through in vitro culture of tumor cells harvested by prostatic massage. Eur Urol 1993;24:148-55.
15. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-77.
16. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7: 728-35.
17. Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 2000;57:41-64.
18. Murphy GP, Boynton AL, Holmes EH, Barren RJ. Non-invasive methods to detect prostate cancer. US patent 6,200,765. 2001 March 13.
19. Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. Acta Cytol 1985;29:810-6.
20. Wawroschek F, Rathert P. Urine cytology. Urologe A 1995;34:69-75.
21. Hess JL, Highsmith WE. Telomerase detection in body fluids. Clin Chem 2002;48:18-24.
22. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987;51:887-98.
23. Blackburn EH. Telomerases. Annu Rev Biochem 1992;61:113-29.
24. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266: 2011-5.
25. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33: 787-91.
26. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.
27. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y. Telomerase activity in primary prostate cancer. J Urol 1997;157:1161-5.
28. Lin Y, Uemura H, Fujinami K, et al. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 1998;36:121-8.
29. Wymenga LF, Wisman GB, Veenstra R, Ruiters MH, Mensink HJ. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur J Clin Invest 2000;30:275-6, 330-5.
30. Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol 1997;50:106-9.
31. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82.
32. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.
33. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-73.
34. Hiyama E, Hiyama K. Clinical utility of telomerase in cancer. Oncogene 2002;21:643-9.
35. Vicentini C, Gravina GL, Angelucci A, et al. Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 2004; 130:217-21.
36. Kinoshita H, Ogawa O, Kakehi Y, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-30.
37. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
38. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-21.
39. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166: 666-73.
40. Caldarera E, Crooks NH, Muir GH, Pavone-Macaluso M, Carmichael PL. An appraisal of telomerase activity in benign prostatic hyperplasia. Prostate 2000;45:267-70.
41. Wang Z, Ramin SA, Tsai C, et al. Detection of telomerase activity in prostatic fluid specimens. Urol Oncol 2000;6:4-9.
42. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol 2001;165:1802-5.
43. Wu YY, Hruszkewycz AM, Delgado RM, et al. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin Chim Acta 2000; 293:199-212.
44. Hou M, Xu D, Bjorkholm M, Gruber A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin Chem 2001;47:519-24.
45. Boddy JL, Pike DJ, Malone PR. A seven-year follow-up of men following a benign prostate biopsy. Eur Urol 2003;44:17-20.
46. Wang Z, Ramin SA, Tsai C, et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol 2001;6: 57-62.
47. Botchkina IL, Rowehl R, Botchkina GI. Telomerase activity analysis in human cell lines using a real-time PCR (RTQ-TRAP) assay. Proc of the AACR 2004; 45:994.
48. Kinoshita Y, Singh A, Rovito PM, Wang CY, Haas GP. Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer 2004;3:83-6.